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CONCLUSIONS: SSP with perindopril/indapamid saves
lives and Health care costs.
CV2
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OBJECTIVES: Accurate information about resources use
and costs of stroke is necessary for informed health plan-
ning activities. The aim of this study was to determine the
patterns of health resources use among stroke patients
and to estimate the total costs (direct medical and non
medical and indirect production losses) of stroke in Spain
for 2001. METHODS: The cost-of-illness method was
used. Direct and indirect costs were estimated using
prevalence costs. Indirect costs (productivity costs) were
estimated using the approach of human capital theory
from lost earning attributable to stroke related mortality
and morbidity. Data on resource use were retrospectively
collected from hospitals and questionnaires. The costs of
stroke during the ﬁrst, second and third year after stroke
and the total costs of stroke were estimated. RESULTS:
We gathered information from 350 patients. The average
cost per stroke survivor during the ﬁrst, second and third
year, in Spain during 2001, were estimated to be €10,189,
€7,662, and €5,614 respectively. The most important 
categories of cost during the ﬁrst year were acute hospi-
talisation and rehabilitation. During the second and third
year the most important categories of costs were drugs,
rehabilitation and tests. Stroke cost €1402.34 million to
the Spanish health care system, representing 4% of the
total public health care expenditure, €3197.55 million in
informal care and €392.95 million for productivity loss.
The total annual cost of all stroke related burden was
€4992.84 million. CONCLUSIONS: Stroke is a leading
public health problem in Spain in term of the economic
burden of disease. Given the magnitude of these costs,
investigation of the cost-effectiveness of different inter-
ventions for stroke should become a priority.
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OBJECTIVES: The risk of VTE after hip fracture surgery
has been clearly demonstrated by randomized clinical
trials designed for the registration of a new anti-
thrombotic agent. Nevertheless as the diagnosis of VTE
was based on a systematic venography which is not rou-
tinely performed in current practice, real life data based
on the occurence of clinical events are needed from both
an epidemiological and economic point of view.
METHODS: The VEEP (VEnous Embolism in hiP frac-
ture) cohort study was a prospective cohort study run in
two sizeable French public hospitals. During a 1-year
period, patients hospitalized for hip fracture were con-
secutively included and followed up for three months.
Resource use data concerning type of surgery, anti-throm-
botic treatments (preventive, curative) and clinical events
(Deep Vein Thrombosis, Pulmonary Embolism, bleed-
ings) were collected. RESULTS: One hundred sixty-nine
patients were included in the cohort study (mean age 84.6
years, 82% female). History of previous VTE was found
in 15% of the patients. Mean length of stay in acute care
was 16.1 days (+/-11). Mean length of stay in rehabili-
tation unit was 41.6 days (+/-22.7). A total of 162
patients received an antithrombotic treatment post-oper-
atively (in most of cases a low molecular weight heparin).
The cumulative rate of VTE clinically suspected and con-
ﬁrmed by echo-doppler was higher than expected (13.6%
at 3 months) and 80% of the VTE events occur after dis-
charge from acute care. Only one pulmonary embolism
was reported. Length of stay was signiﬁcantly higher in
patients having experienced a VTE (nine additional days
on an average) leading to substantial additional costs.
CONCLUSION: Despite standard antithrombotic pro-
phylaxis the risk of clinical VTE is high after hip fracture
surgery and even higher after the acute phase, highlight-
ing the need for more effective preventive therapies.
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OBJECTIVE: To project the life expectancy (LE) and
costs of treating patients with diabetes, hypertension, and
microalbuminuria with irbesartan 300mg. METHODS:
A long-term Markov model simulated progression from
microalbuminuria to nephropathy, doubling of serum 
creatinine, end-stage renal disease (ESRD), and all-cause
616 Abstracts
mortality in patients with hypertension, type 2 diabetes
and microalbuminuria. Three strategies were compared:
early use of irbesartan (begun in subjects with microal-
buminuria), late use of irbesartan (begun only in subjects
with nephropathy), and standard hypertension care (with
comparable blood pressure control). The model was
based on data from the Irbesartan in Reduction of
Microalbuminuria-II study and the Irbesartan and 
Diabetic Nephropathy Trial. Both studies demonstrated
signiﬁcant reductions in the progression of diabetic renal
disease. ESRD-related costs and outcomes were retrieved
from the French-speciﬁc published or ofﬁcial sources.
Cost savings and life years saved were projected for a
hypothetical cohort of 1000 subjects with baseline age 58
years. Future costs and LE were discounted at 3% yearly.
A 25-year time horizon and third party payer perspective
were used. Extensive sensitivity analyses were performed.
RESULTS: When compared to standard care, early use of
irbesartan in 1000 subjects was projected to save €25.7
million (95%CI 16.8–32.3), while late use of irbesartan
was projected to save €9.2 (3.4–14.1) million. Similarly,
early use of irbesartan was estimated to add 796
(520–1050) life years, while late use of irbesartan added
60 (22–92) life years. The superiority of early use of irbe-
sartan over late use and standard care was robust under
a wide range of plausible assumptions. CONCLUSIONS:
Treating patients with hypertension, microalbuminuria
and type 2 diabetes with irbesartan was projected to
extend life and reduce costs. Late use of irbesartan (when
overt nephropathy develops) is also better and less costly
than standard care, but irbesartan should be started
earlier and continued long-term.
MAKING EVALUATIONS WORK
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OBJECTIVES: Multi-country trial-based cost-
effectiveness analyses often assume that resource utilisa-
tion and clinical efﬁcacy are not country-speciﬁc, and
apply country-speciﬁc unit costs. We applied economet-
ric methods to estimate country-speciﬁc cost-
effectiveness, adjusting for differences in incremental
resource utilisation and case mix across countries. Results
with and without adjustment are compared and methods
described. METHODS: The TARGET multinational trial
compared cure within 21 days for patients with CAP
between sequential IV/PO moxiﬂoxacin monotherapy
and standard comparators. Unit costs were available for
4 countries (France, Germany, Spain, UK) among 10. A
previously published framework, based on a system of
regression equations, was used to determine treatment
impact on resource use and outcome by country, con-
trolling for baseline characteristics. Clinical efﬁcacy was
held constant across countries, but the impact of cure on
resource utilisation was allowed to vary. Bootstrapping
was also used to estimate uncertainty around country-
speciﬁc cost-effectiveness results. RESULTS: No signiﬁ-
cant inter-country variation in clinical efﬁcacy was
observed (p = 0.9843). Treatment increased the proba-
bility of cure by 5% and the impact of cure on resource
use varied signiﬁcantly across countries (p < 0.0001).
However between-country differences in incremental
resource utilisation were not detected statistically (p =
0.7759) so that unadjusted analysis was also a possible
approach. Using country-speciﬁc unit prices, average
incremental costs per patient non-adjusted and adjusted
were €-266 and €-436 for Germany, €-381 and €-543
for France, €-281 and €+126 for Spain, €-360 and 
€-1192 for UK. The probability that moxiﬂoxacin is cost-
saving was 97% for Germany, 95% for France, 90% for
Spain and 87% for the UK in the non-adjusted analyses
compared to 99%, 66%, 41% and near 100%. CON-
CLUSIONS: Where study treatments impact resource 
use differently across countries or country-speciﬁc CEA
is desired, adjusted results can differ substantially.
Although improved country-speciﬁcity is associated with
increased variation in cost, country-speciﬁc cost-
effectiveness measures may be more informative.
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OBJECTIVE: Development of a user-friendly tool for the
evaluation and improvement of the transferability of eco-
nomic evaluation results. METHODS: We systematically
identiﬁed the factors that may inﬂuence the transfer of
study results and investigated the way they impact trans-
ferability. A transferability decision chart was developed
that includes knock out criteria, a checklist based on the
transferability factors, and methods for improving trans-
ferability and for assessing the uncertainty of transferred
results. The decision chart was applied to various inter-
national cost-effectiveness studies. RESULTS: Economic
evaluation results can be transferred pending the out-
comes of the transferability check and necessary adjust-
ments. The inﬂuence of differences of most transferability
factors can be estimated via the key health economic
determinants capacity utilization, effectiveness, produc-
tivity loss and returns to scale. Depending on the results
of the transferability check an adjustment of the study
results for inﬂation and for differences related to curren-
cies or purchasing power might be sufﬁcient. Otherwise,
